Author Archives: Kerry Dooley Young and Liz Seegert

About Kerry Dooley Young and Liz Seegert

Kerry Dooley Young is an independent journalist and AHCJ's core topic leader on patient safety. Liz Seegert, based in New York City, is AHCJ’s topic leader on aging.

Biden’s bid for a nursing home vaccine mandate faces obstacles

Photo: Wyoming National Guard via Flickr

EDITOR’S NOTE: This is the second in a series about the Biden Administration’s efforts to increase COVID-19 vaccination rates among nursing home workers. For the first story see: Federal funds at stake as Biden Administration seeks to require vaccines for nursing home workers

The Biden administration likely will face challenges in trying to implement a planned mandate for COVID-19 vaccinations for staff of nursing homes, despite efforts to portray this proposal as a done deal. Continue reading

Disease-awareness campaigns merit extra scrutiny, experts say

Image by Alvin Gogineni, Genentech via NIH Image Gallery on Flickr

Image by Alvin Gogineni, Genentech via NIH Image Gallery on Flickr

This is part 2 of a package on sponsored disease awareness campaigns and other controversial drug marketing practices, focusing on Biogen’s efforts to build a market for its recently approved drug for Alzheimer’s disease. Check out part 1, which posted on August 4.

Biogen’s marketing campaigns about mild cognitive impairment drew protests from several physicians, but don’t expect federal regulators to more strictly regulate such ads and similar disease-awareness promotions.

Neither the FDA nor the FTC actively monitors claims made in pharmaceutical marketing about medical conditions if the name of a medicine isn’t mentioned. Continue reading

Explaining Biogen’s controversial ‘MCI’ advertising to your audience

New marketing campaigns about forgetfulness and distraction could lead people to seek the costly Aduhelm drug for Alzheimer’s disease even if they haven’t been diagnosed with the condition, several experts have warned.

By working to expand the market of people seeking treatment for mild cognitive impairment,  Biogen could needlessly expose many people to a drug with known risk but as yet unproven potential benefit, some researchers said. (See “Do we all have Alzheimer’s? Drug makers might want you to think so,” Adriane Fugh-Berman and Patricia Bencivenga of Georgetown University, Baltimore Sun, July 16, and “‘When Memory Fades’: Misinformation about Alzheimer’s disease and Aduhelm must be limited,” Madhav Thambisetty of Johns Hopkins University, STAT, July 21.) Continue reading